Yes, I did comment on the fact they were broke (didn't use that term), but Febridx was in the European market, not US, so I did say, pre US approval.
The company had a market cap of circa $188Million art IPO based on the assumption the FDA approval was there and an assume CLIA waiver status. They did also however have 2 other LDX branded products in development which ceased also.
But on the logic of 50% of the overall US approval, technically we should be at $94Million market cap
Just highlighting that it is neglectful to assume this still cant go to .001c just because we have cash in the bank.
Market clearly doesn't value the Hologic deal and BARDA funding etc any more than when we didn't have these deals or FDA approval, as reflected in the SP:
The bump up in the last push before FDA approval was the 3 Hologic deal announcement which included the leaseback etc to provide the cash noted in the Quarterly I discussed.
It basically means everything here is not being factored in to any value right now:
If it did, we should be sitting around .05c+ right now.
Add to My Watchlist
What is My Watchlist?
